Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal CancerJenny F. Seligmann, Michel Seymour, Philip Quirke et al.|JAMA Oncology|2016Cited by 115
Association of Tumor <i>HER3</i> Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F. Seligmann, Michel Seymour, Ace J. Hatch et al.|JAMA Oncology|2017Cited by 29
Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panelJenny F. Seligmann, Michel Seymour, Faye Elliott et al.|Annals of Oncology|2020Cited by 18
HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in <i>RAS</i>-wt advanced colorectal cancer (aCRC).Jenny F. Seligmann, Andrew B. Nixon, Faye Elliott et al.|Journal of Clinical Oncology|2015Cited by 1